Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.

Duration of PFS is defined as the time of randomization to the earlier of the following events: progressive disease or death due to any cause.

Objective Response Rate (ORR) [ Time Frame: Up to 38 months ]

ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment. ORR is the proportion of subjects experiencing a confirmed complete response(CR) or confirmed partial response (PR).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Select Inclusion Criteria:

Histological or cytological diagnosis of HCC.

The subject has disease that is not amenable to a curative treatment approach.

Received prior sorafenib.

Progression following at least 1 prior systemic treatment for HCC.

Recovery to from toxicities related to any prior treatments.

ECOG performance status of 0 or 1.

Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within 7 days before randomization.

Child-Pugh Score of A.

Antiviral therapy per local standard of care if active hepatitis B (HBV) infection.

Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.

Female subjects of childbearing potential must not be pregnant at screening.

Select Exclusion Criteria:

Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.

Receipt of more than 2 prior systemic therapies for advanced HCC.

Any type of anticancer agent (including investigational) within 2 weeks before randomization.

Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment within 6 weeks of randomization.

Prior cabozantinib treatment.

Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.